Inventor
WOLL STEFAN
DE15 patents
⚠️ This page may combine multiple inventors who share the name “WOLL STEFAN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
GANYMED PHARMACEUTICALS AG
9 patentsUS10233253B2Mar 19, 2019
Antibodies for treatment of cancer expressing claudin 6
GANYMED PHARMACEUTICALS AG7 citations83
US10053512B2Aug 21, 2018
Antibodies against claudin 18.2 useful in cancer diagnosis
GANYMED PHARMACEUTICALS AG6 citations83
US10314890B2Jun 11, 2019
Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic cancer
GANYMED PHARMACEUTICALS AG5 citations82
US9770487B2Sep 26, 2017
Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic adenocarcinoma
GANYMED PHARMACEUTICALS AG11 citations82
US11976130B2May 7, 2024
Antibodies against claudin 18.2 useful in cancer diagnosis
GANYMED PHARMACEUTICALS AG0 citations62
US10919974B2Feb 16, 2021
Antibodies for treatment of cancer expressing claudin 6
GANYMED PHARMACEUTICALS AG0 citations61
US9932401B2Apr 3, 2018
Antibodies specific for claudin 6 (CLDN6)
GANYMED PHARMACEUTICALS AG1 citations61
US11473085B2Oct 18, 2022
Methods and compositions for diagnosis and treatment of cancer
GANYMED PHARMACEUTICALS AG1 citations57
US10745477B2Aug 18, 2020
Antibodies specific for claudin 6 (CLDN6)
GANYMED PHARMACEUTICALS AG0 citations51
SAHIN UGUR
2 patentsGANYMED PHARMACEUTICALS GMBH
2 patentsASTELLAS PHARMA INC
2 patentsUS11826402B2Nov 28, 2023
Combination therapy involving antibodies against claudin 18.2 for treatment of metastatic pancreatic adenocarcinoma
ASTELLAS PHARMA INC0 citations61
US10946069B2Mar 16, 2021
Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic cancer
ASTELLAS PHARMA INC0 citations61